APO Research
Talk to an analyst

APO RESEARCH · REPORT

Adeno Associated Virus Production

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Adeno Associated Virus Production Market Outlook and Growth Opportunities 2026

1 May 2026193 pages

Choose your research edition.

Industry ResearchAdeno Associated Virus Production Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Adeno Associated Virus Production Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Adeno Associated Virus Production Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adeno Associated Virus Production Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Adeno Associated Virus Production Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Adeno Associated Virus Production market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Adeno Associated Virus Production is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Adeno Associated Virus Production is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Adeno Associated Virus Production is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Adeno Associated Virus Production market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Adeno Associated Virus Production market include Biovian, Charles River, Lonza, Merck Group, OriGene, Sigma-Aldrich, SIRION Biotech, Thermo Fisher Scientific and Vigene Biosciences, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Adeno Associated Virus Production market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Adeno Associated Virus Production and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Adeno Associated Virus Production revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Adeno Associated Virus Production market.

Adeno Associated Virus Production Segment by Company

Biovian

Charles River

Lonza

Merck Group

OriGene

Sigma-Aldrich

SIRION Biotech

Thermo Fisher Scientific

Vigene Biosciences

Yeasen Aav

Adeno Associated Virus Production Segment by Type

Large-Scale Production

Customized Production

Adeno Associated Virus Production Segment by Application

Vaccine Production

Gene Therapy

Others

Adeno Associated Virus Production Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Adeno Associated Virus Production status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Adeno Associated Virus Production key companies, revenue, market share, and recent developments.

3. To split the Adeno Associated Virus Production breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Adeno Associated Virus Production market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Adeno Associated Virus Production significant trends, drivers, influence factors in global and regions.

6. To analyze Adeno Associated Virus Production competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adeno Associated Virus Production market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adeno Associated Virus Production and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adeno Associated Virus Production.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Adeno Associated Virus Production industry.

Chapter 3: Detailed analysis of Adeno Associated Virus Production company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Adeno Associated Virus Production in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Adeno Associated Virus Production in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Adeno Associated Virus Production Industry Trends Table 2. Adeno Associated Virus Production Industry Drivers Table 3. Adeno Associated Virus Production Industry Opportunities and Challenges Table 4. Adeno Associated Virus Production Industry Restraints Table 5. Global Adeno Associated Virus Production Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Adeno Associated Virus Production Revenue Share by Company (2021-2026) Table 7. Global Adeno Associated Virus Production Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Adeno Associated Virus Production Key Company Manufacturing Base & Headquarters Table 9. Global Adeno Associated Virus Production Company, Product Type & Application Table 10. Global Adeno Associated Virus Production Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Adeno Associated Virus Production by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Large-Scale Production Table 15. Significant Companies of Customized Production Table 16. Global Adeno Associated Virus Production Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Adeno Associated Virus Production Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Adeno Associated Virus Production Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Adeno Associated Virus Production Sales Value Share by Type (2021-2026) Table 20. Global Adeno Associated Virus Production Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Vaccine Production Table 22. Significant Companies of Gene Therapy Table 23. Significant Companies of Others Table 24. Global Adeno Associated Virus Production Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Adeno Associated Virus Production Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Adeno Associated Virus Production Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Adeno Associated Virus Production Sales Value Share by Application (2021-2026) Table 28. Global Adeno Associated Virus Production Sales Value Share by Application (2027-2032) Table 29. Global Adeno Associated Virus Production Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Adeno Associated Virus Production Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Adeno Associated Virus Production Sales Value Share by Region (2021-2026) Table 32. Global Adeno Associated Virus Production Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Adeno Associated Virus Production Sales Value Share by Region (2027-2032) Table 34. Global Adeno Associated Virus Production Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Adeno Associated Virus Production Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Adeno Associated Virus Production Sales Value Market Share by Country (2021-2026) Table 37. Global Adeno Associated Virus Production Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Adeno Associated Virus Production Sales Value Market Share by Country (2027-2032) Table 39. Biovian Company Information Table 40. Biovian Business Overview Table 41. Biovian Adeno Associated Virus Production Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Biovian Adeno Associated Virus Production Product Portfolio Table 43. Biovian Recent Development Table 44. Charles River Company Information Table 45. Charles River Business Overview Table 46. Charles River Adeno Associated Virus Production Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Charles River Adeno Associated Virus Production Product Portfolio Table 48. Charles River Recent Development Table 49. Lonza Company Information Table 50. Lonza Business Overview Table 51. Lonza Adeno Associated Virus Production Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Lonza Adeno Associated Virus Production Product Portfolio Table 53. Lonza Recent Development Table 54. Merck Group Company Information Table 55. Merck Group Business Overview Table 56. Merck Group Adeno Associated Virus Production Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Merck Group Adeno Associated Virus Production Product Portfolio Table 58. Merck Group Recent Development Table 59. OriGene Company Information Table 60. OriGene Business Overview Table 61. OriGene Adeno Associated Virus Production Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. OriGene Adeno Associated Virus Production Product Portfolio Table 63. OriGene Recent Development Table 64. Sigma-Aldrich Company Information Table 65. Sigma-Aldrich Business Overview Table 66. Sigma-Aldrich Adeno Associated Virus Production Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Sigma-Aldrich Adeno Associated Virus Production Product Portfolio Table 68. Sigma-Aldrich Recent Development Table 69. SIRION Biotech Company Information Table 70. SIRION Biotech Business Overview Table 71. SIRION Biotech Adeno Associated Virus Production Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. SIRION Biotech Adeno Associated Virus Production Product Portfolio Table 73. SIRION Biotech Recent Development Table 74. Thermo Fisher Scientific Company Information Table 75. Thermo Fisher Scientific Business Overview Table 76. Thermo Fisher Scientific Adeno Associated Virus Production Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Thermo Fisher Scientific Adeno Associated Virus Production Product Portfolio Table 78. Thermo Fisher Scientific Recent Development Table 79. Vigene Biosciences Company Information Table 80. Vigene Biosciences Business Overview Table 81. Vigene Biosciences Adeno Associated Virus Production Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Vigene Biosciences Adeno Associated Virus Production Product Portfolio Table 83. Vigene Biosciences Recent Development Table 84. Yeasen Aav Company Information Table 85. Yeasen Aav Business Overview Table 86. Yeasen Aav Adeno Associated Virus Production Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Yeasen Aav Adeno Associated Virus Production Product Portfolio Table 88. Yeasen Aav Recent Development Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Adeno Associated Virus Production Product Image Figure 2. Global Adeno Associated Virus Production Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Adeno Associated Virus Production Market Size (2021-2032) & (US$ Million) Figure 4. Global Adeno Associated Virus Production Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Large-Scale Production Image Figure 8. Customized Production Image Figure 9. Global Adeno Associated Virus Production Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Adeno Associated Virus Production Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Adeno Associated Virus Production Sales Value Share by Type (2021-2032) Figure 12. Vaccine Production Image Figure 13. Gene Therapy Image Figure 14. Others Image Figure 15. Global Adeno Associated Virus Production Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Adeno Associated Virus Production Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Adeno Associated Virus Production Sales Value Share by Application (2021-2032) Figure 18. Global Adeno Associated Virus Production Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Adeno Associated Virus Production Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Adeno Associated Virus Production Sales Value (2021-2032) & (US$ Million) Figure 21. North America Adeno Associated Virus Production Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Adeno Associated Virus Production Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Adeno Associated Virus Production Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Adeno Associated Virus Production Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Adeno Associated Virus Production Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Adeno Associated Virus Production Sales Value (2021-2032) & (US$ Million) Figure 27. South America Adeno Associated Virus Production Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Adeno Associated Virus Production Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Adeno Associated Virus Production Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Adeno Associated Virus Production Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Large-Scale Production
  • Customized Production
Applications
  • Vaccine Production
  • Gene Therapy
  • Others
Companies covered
  • Biovian
  • Charles River
  • Lonza
  • Merck Group
  • OriGene
  • Sigma-Aldrich
  • SIRION Biotech
  • Thermo Fisher Scientific
  • Vigene Biosciences
  • Yeasen Aav

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Adeno Associated Virus Production Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Adeno Associated Virus Production Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Adeno Associated Virus Production Market Dynamics
  1. 2.1 Adeno Associated Virus Production Industry Trends
  2. 2.2 Adeno Associated Virus Production Industry Drivers
  3. 2.3 Adeno Associated Virus Production Industry Opportunities and Challenges
  4. 2.4 Adeno Associated Virus Production Industry Restraints
3 Adeno Associated Virus Production Market by Company
  1. 3.1 Global Adeno Associated Virus Production Company Revenue Ranking in 2025
  2. 3.2 Global Adeno Associated Virus Production Revenue by Company (2021-2026)
  3. 3.3 Global Adeno Associated Virus Production Company Ranking (2024-2026)
  4. 3.4 Global Adeno Associated Virus Production Company Manufacturing Base and Headquarters
  5. 3.5 Global Adeno Associated Virus Production Company Product Type and Application
  6. 3.6 Global Adeno Associated Virus Production Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Adeno Associated Virus Production Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Adeno Associated Virus Production Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Adeno Associated Virus Production Market by Type
  1. 4.1 Adeno Associated Virus Production Type Introduction
  2. 4.1.1 Large-Scale Production
  3. 4.1.2 Customized Production
  4. 4.2 Global Adeno Associated Virus Production Sales Value by Type
  5. 4.2.1 Global Adeno Associated Virus Production Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Adeno Associated Virus Production Sales Value by Type (2021-2032)
  7. 4.2.3 Global Adeno Associated Virus Production Sales Value Share by Type (2021-2032)
5 Adeno Associated Virus Production Market by Application
  1. 5.1 Adeno Associated Virus Production Application Introduction
  2. 5.1.1 Vaccine Production
  3. 5.1.2 Gene Therapy
  4. 5.1.3 Others
  5. 5.2 Global Adeno Associated Virus Production Sales Value by Application
  6. 5.2.1 Global Adeno Associated Virus Production Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Adeno Associated Virus Production Sales Value by Application (2021-2032)
  8. 5.2.3 Global Adeno Associated Virus Production Sales Value Share by Application (2021-2032)
6 Adeno Associated Virus Production Regional Value Analysis
  1. 6.1 Global Adeno Associated Virus Production Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Adeno Associated Virus Production Sales Value by Region (2021-2032)
  3. 6.2.1 Global Adeno Associated Virus Production Sales Value by Region: 2021-2026
  4. 6.2.2 Global Adeno Associated Virus Production Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Adeno Associated Virus Production Sales Value (2021-2032)
  7. 6.3.2 North America Adeno Associated Virus Production Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Adeno Associated Virus Production Sales Value (2021-2032)
  10. 6.4.2 Europe Adeno Associated Virus Production Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Adeno Associated Virus Production Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Adeno Associated Virus Production Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Adeno Associated Virus Production Sales Value (2021-2032)
  16. 6.6.2 South America Adeno Associated Virus Production Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Adeno Associated Virus Production Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Adeno Associated Virus Production Sales Value Share by Country, 2025 VS 2032
7 Adeno Associated Virus Production Country-level Value Analysis
  1. 7.1 Global Adeno Associated Virus Production Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Adeno Associated Virus Production Sales Value by Country (2021-2032)
  3. 7.2.1 Global Adeno Associated Virus Production Sales Value by Country (2021-2026)
  4. 7.2.2 Global Adeno Associated Virus Production Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Adeno Associated Virus Production Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Adeno Associated Virus Production Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Adeno Associated Virus Production Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Biovian
  2. 8.1.1 Biovian Company Information
  3. 8.1.2 Biovian Business Overview
  4. 8.1.3 Biovian Adeno Associated Virus Production Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Biovian Adeno Associated Virus Production Product Portfolio
  6. 8.1.5 Biovian Recent Developments
  7. 8.2 Charles River
  8. 8.2.1 Charles River Company Information
  9. 8.2.2 Charles River Business Overview
  10. 8.2.3 Charles River Adeno Associated Virus Production Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Charles River Adeno Associated Virus Production Product Portfolio
  12. 8.2.5 Charles River Recent Developments
  13. 8.3 Lonza
  14. 8.3.1 Lonza Company Information
  15. 8.3.2 Lonza Business Overview
  16. 8.3.3 Lonza Adeno Associated Virus Production Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Lonza Adeno Associated Virus Production Product Portfolio
  18. 8.3.5 Lonza Recent Developments
  19. 8.4 Merck Group
  20. 8.4.1 Merck Group Company Information
  21. 8.4.2 Merck Group Business Overview
  22. 8.4.3 Merck Group Adeno Associated Virus Production Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck Group Adeno Associated Virus Production Product Portfolio
  24. 8.4.5 Merck Group Recent Developments
  25. 8.5 OriGene
  26. 8.5.1 OriGene Company Information
  27. 8.5.2 OriGene Business Overview
  28. 8.5.3 OriGene Adeno Associated Virus Production Revenue and Gross Margin (2021-2026)
  29. 8.5.4 OriGene Adeno Associated Virus Production Product Portfolio
  30. 8.5.5 OriGene Recent Developments
  31. 8.6 Sigma-Aldrich
  32. 8.6.1 Sigma-Aldrich Company Information
  33. 8.6.2 Sigma-Aldrich Business Overview
  34. 8.6.3 Sigma-Aldrich Adeno Associated Virus Production Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sigma-Aldrich Adeno Associated Virus Production Product Portfolio
  36. 8.6.5 Sigma-Aldrich Recent Developments
  37. 8.7 SIRION Biotech
  38. 8.7.1 SIRION Biotech Company Information
  39. 8.7.2 SIRION Biotech Business Overview
  40. 8.7.3 SIRION Biotech Adeno Associated Virus Production Revenue and Gross Margin (2021-2026)
  41. 8.7.4 SIRION Biotech Adeno Associated Virus Production Product Portfolio
  42. 8.7.5 SIRION Biotech Recent Developments
  43. 8.8 Thermo Fisher Scientific
  44. 8.8.1 Thermo Fisher Scientific Company Information
  45. 8.8.2 Thermo Fisher Scientific Business Overview
  46. 8.8.3 Thermo Fisher Scientific Adeno Associated Virus Production Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Thermo Fisher Scientific Adeno Associated Virus Production Product Portfolio
  48. 8.8.5 Thermo Fisher Scientific Recent Developments
  49. 8.9 Vigene Biosciences
  50. 8.9.1 Vigene Biosciences Company Information
  51. 8.9.2 Vigene Biosciences Business Overview
  52. 8.9.3 Vigene Biosciences Adeno Associated Virus Production Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Vigene Biosciences Adeno Associated Virus Production Product Portfolio
  54. 8.9.5 Vigene Biosciences Recent Developments
  55. 8.10 Yeasen Aav
  56. 8.10.1 Yeasen Aav Company Information
  57. 8.10.2 Yeasen Aav Business Overview
  58. 8.10.3 Yeasen Aav Adeno Associated Virus Production Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Yeasen Aav Adeno Associated Virus Production Product Portfolio
  60. 8.10.5 Yeasen Aav Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst